Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 10, 2013, Pages 4030-4037

  Yamamoto, Masahiro ^a   Yamauchi, Mika ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SCLEROSTIN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SPINE FRACTURE; SPINE RADIOGRAPHY;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; RISK; SPINAL FRACTURES;

EID: 84885237881     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2143     Document Type: Article

References (27)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int. 2007; 18: 427-444.
2. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int. 2007; 18: 427-444.
3. Janghorbani M, Van Dam RM, Willett WC, Hu FB Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166: 495-505.
4. Yamamoto M, Yamaguchi T, Yamauchi M., Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009; 24: 702-709.
5. Schwartz AV, Vittinghoff E, Bauer D.C., et al Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011; 305: 2184-2192.
6. Anonymous 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785-795.
7. Moester MJ, Papapoulos SE, Lowik C.W., van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010; 87: 99-107.
8. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280: 26770-26775.
9. Ellies DL, Viviano B, McCarthy J, et al. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006; 21: 1738-1749.
10. Li X, Zhang Y, Kang H., et al Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883-19887.
11. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research study. J Bone Miner Res. 2012; 27: 2592-2602.
12. Arasu A, Cawthon PM, Lui L.Y., et al.; Study of Osteoporotic Fractures Research Group. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab. 2012; 97: 2027-2032.
13. Genant HK, Wu CY, van Kuijk C, Nevitt MC Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137-1148.
14. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W., Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women: the six-month effect of risedronate and teriparatide. Osteoporos Int. 2012; 23: 1171-1176.
15. Sheng Z, Tong D, Ou Y., et al Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf). 2012; 76: 797-801.
16. Modder UI, Hoey KA, Amin S, et al Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011; 26: 373-379.
17. Ardawi MS, Al-Kadi HA, Rouzi A.A., Qari MH Determinants of serum sclerostin in healthy pre- and post menopausal women. J Bone Miner Res. 2011; 26: 2812-2822.
18. Garcia-Martin A., Rozas-Moreno P, Reyes-Garcia R, et al Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97: 234-241.
19. Garnero P, Sornay-Rendu E, Munoz F., Borel O, Chapurlat RD Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013; 24: 489-494.
20. Szulc P, Bertholon C, Borel O., Marchand F, Chapurlat R. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res. 2013; 28: 855-864.
21. Dallas SL, Bonewald LF Dynamics of the transition from osteoblast to osteocyte. Ann N Y Acad Sci. 2010; 1192: 437-443.
22. Gennari L, Merlotti D, Valenti R., et al Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012; 97: 1737-1744.
23. Gaudio A, Privitera F, Battaglia K., et al Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97: 3744-3750.
24. Amrein K, Amrein S, Drexler C., et al Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012; 97: 148-154.
25. van Lierop A.H., Hamdy NA, van der Meer RW, et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol. 2012; 166: 711-716.
26. Loke YK, Singh S, Furberg CD Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009; 180: 32-39.
27. Bazelier MT, de Vries F, Vestergaard P, et al Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol. 2013; 4: 11.